II. Indications

  1. Neuraminidase Inhibitors covers both Influenza A and Influenza B
  2. Indicated in hospitalized Influenza patients with <2 days of symptoms AND
  3. Unable to take oral Oseltamivir (Tamiflu)

III. Precautions

IV. Efficacy

  1. IV Antiviral with no better efficacy than Oseltamivir (Tamiflu) except in resistant cases, at 10 times the cost

V. Dosing

  1. Adult
    1. Dose 600 mg IV over 15 to 30 minutes as single dose
    2. Off label, Peramivir is continued for 5 days (until able to switch to Oseltamivir )
  2. Child (age >= 6 years, per CDC, not FDA approved)
    1. Dose 10 mg/kg (up to 600 mg) IV over 15 to 30 minutes daily for 5 days
  3. Renal Dosing
    1. Administer doses after Hemodialysis
    2. Age 2 to 12 years old
      1. eGFR 30 to 49: 4 mg/kg (up to 600 mg) IV daily
      2. eGFR 10 to 29: 2 mg/kg (up to 600 mg) IV daily
    3. Age >=13 years (and adults)
      1. eGFR 30 to 49: 200 mg IV daily
      2. eGFR 10 to 29: 100 mg IV daily

VI. Adverse effects

  1. Diarrhea (common with Peramivir)
  2. Neuropsychiatric effects
  3. Stevens-Johnson Syndrome (rare)

VII. Safety

  1. Unknown safety in Pregnancy
  2. Unknown safety in Lactation

Images: Related links to external sites (from Bing)

Related Studies

Ontology: peramivir (C1675326)

Definition (NCI) A cyclopentane derivative with activity against influenza A and B viruses. Peramivir is a neuraminidase inhibitor which prevents normal processing of virus particles such that virus particles are not released from infected cells.
Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C414210
English Peramivir, (1S,2S,3R,4R)-3-((1S)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino-2-hydroxycyclopentanecarboxylic acid, trihydrate, peramivir, PERAMIVIR, 3-(1-acetamido-2-ethyl-butyl)-4-guanidino-2-hydroxy-cyclopentane-1-carboxylic acid